Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197921 | 0.90 | GRM5 (0.77) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4193959 | 0.85 | GRM5 (0.80) | GRM5KCNH2 | |
| SCHEMBL5223474 | 0.83 | GRM5 (0.74) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4194639 | 0.83 | GRM5 (0.74) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL30079793 | 0.83 | GRM5 (1.00) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4186520 | 0.83 | GRM5 (1.00) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4198125 | 0.81 | GRM5 (0.67) | GRM5KCNH2S1PR1 | |
| SCHEMBL4192844 | 0.80 | GRM5 (0.73) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4181866 | 0.80 | GRM5 (0.69) | GRM5KCNH2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL4186533 | 0.80 | GRM5 (0.69) | GRM5KCNH2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | GRM5 582/4885KCNH2 3309/4885CHRNB2 1624/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | GRM5 1/4885KCNH2 693/4885CHRNB2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.